David Mintell, MD
Internal Medicine · East Hartford, CTNPI 1366453243
Payments from drug & device makers
Across 123 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$170
- Amgen$139
- GSK$129
- Novo Nordisk$123
- Merck$115
- Lilly USA, LLC$110
- plus $1K from 23 others
What the payments were for
- Food & beverage$1,873100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $170 |
| Amgen | 7 | $139 |
| GSK | 11 | $129 |
| Novo Nordisk | 10 | $123 |
| Merck | 9 | $115 |
| Lilly USA, LLC | 9 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $91 |
| Pfizer | 6 | $86 |
| Boehringer Ingelheim | 4 | $80 |
| AstraZeneca | 5 | $78 |
| MDD US Operations, LLC | 3 | $65 |
| Novartis | 3 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $64 |
| Scilex Pharmaceuticals Inc. | 3 | $62 |
| Neurocrine Biosciences, Inc. | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Astellas Pharma US Inc | 3 | $46 |
| Bristol Myers Squibb | 2 | $46 |
| Radius Health, Inc. | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $30 |
| Aytu Biopharma, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Metuchen Pharmaceuticals | 1 | $12 |
| Pacira Therapeutics, Inc. | 1 | $11 |
How this compares
$1,873 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 152 | $160,668 |
| JardianceEmpagliflozin | 74 | $105,816 |
| OzempicSemaglutide | 56 | $66,595 |
| FarxigaDapagliflozin Propanediol | 35 | $60,304 |
| JanuviaSitagliptin Phosphate | 27 | $40,814 |
| XareltoRivaroxaban | 32 | $39,794 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $38,022 |
| MyrbetriqMirabegron | 54 | $36,123 |
| LinzessLinaclotide | 28 | $30,362 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 32 | $29,800 |
| ProliaDenosumab | 15 | $26,375 |
| TrulicityDulaglutide | 12 | $21,234 |
| Bydureon BciseExenatide Microspheres | 13 | $16,952 |
| MounjaroTirzepatide | 15 | $16,065 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $14,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $86 | $160,668152 claims |
| MerckJanuvia, Janumet, Janumet Xr | $115 | $108,63691 claims |
| Boehringer IngelheimJardiance | $80 | $105,81674 claims |
| AstraZenecaFarxiga, Symbicort | $78 | $67,49452 claims |
| Novo NordiskOzempic | $123 | $66,59556 claims |
| Johnson & JohnsonXarelto | $31 | $39,79432 claims |
| AbbVieLinzess, Synthroid | $170 | $38,875135 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $110 | $37,30027 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $36,12354 claims |
| AmgenProlia | $139 | $26,37515 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $64 | $18,70348 claims |
| GSKAnoro Ellipta | $129 | $9,75515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in East Hartford
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
- Margaret ChusteckaHamden$652K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.